Home Cart Sign in  
Chemical Structure| 1074-79-9 Chemical Structure| 1074-79-9

Structure of Ac-DL-Pro-OH
CAS No.: 1074-79-9

Chemical Structure| 1074-79-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1074-79-9 ]

CAS No. :1074-79-9
Formula : C7H11NO3
M.W : 157.17
SMILES Code : O=C(C1N(C(C)=O)CCC1)O
MDL No. :MFCD00063230
InChI Key :GNMSLDIYJOSUSW-UHFFFAOYSA-N
Pubchem ID :322640

Safety of [ 1074-79-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Computational Chemistry of [ 1074-79-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 0
Fraction Csp3 0.71
Num. rotatable bonds 2
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 42.43
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

57.61 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.13
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.69
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.3
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.2
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.09
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.03

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.25
Solubility 88.8 mg/ml ; 0.565 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.04
Solubility 142.0 mg/ml ; 0.902 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.21
Solubility 254.0 mg/ml ; 1.62 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.75 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.73

Application In Synthesis of [ 1074-79-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1074-79-9 ]

[ 1074-79-9 ] Synthesis Path-Downstream   1~35

  • 3
  • [ 73323-64-5 ]
  • [ 1074-79-9 ]
  • 4
  • [ 16115-80-3 ]
  • [ 1074-79-9 ]
  • 2-[(1-Acetyl-pyrrolidine-2-carbonyl)-amino]-malonic acid dimethyl ester [ No CAS ]
  • 6
  • [ 1074-79-9 ]
  • 3-Methyl-1-oxo-5,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]oxazol-4-ylium; perchlorate [ No CAS ]
  • 7
  • [ 1074-79-9 ]
  • [ 147-85-3 ]
  • 9
  • [ 75-31-0 ]
  • [ 1074-79-9 ]
  • N-acetyl-DL-proline isopropylamide [ No CAS ]
  • 10
  • [ 1147550-11-5 ]
  • [ 108-24-7 ]
  • [ 1074-79-9 ]
  • [ 61160-12-1 ]
  • 11
  • [ 5638-76-6 ]
  • [ 1074-79-9 ]
  • (S)-1-Acetyl-pyrrolidine-2-carboxylic acid methyl-(2-pyridin-2-yl-ethyl)-amide [ No CAS ]
  • 14
  • (R)-1-acetylpyrrolidine-2-carboxylic acid [ No CAS ]
  • [ 1074-79-9 ]
  • 15
  • [ 100-46-9 ]
  • [ 1074-79-9 ]
  • 1-acetyl-pyrrolidine-2-carboxylic acid benzylamide [ No CAS ]
  • 18
  • [ 1074-79-9 ]
  • 1-[2-(4-methyl-benzoyl)-pyrrolidin-1-yl]-ethanone [ No CAS ]
  • 19
  • [ 1074-79-9 ]
  • 1-(6-hydroxy-6-p-tolyl-5-aza-bicylco[2.1.1]hex-5-yl)ethanone [ No CAS ]
  • 20
  • [ 1074-79-9 ]
  • C13H13N5O2 [ No CAS ]
  • 21
  • [ 1074-79-9 ]
  • 7-Oxo-3b,4,5,6-tetrahydro-7H-1,3,6a,11b-tetraaza-benzo[g]cyclopenta[e]azulene-2-carboxylic acid methyl ester [ No CAS ]
  • 22
  • [ 1074-79-9 ]
  • 5-(1-Acetyl-pyrrolidin-2-yl)-1-(2-chloro-pyridin-3-yl)-1H-[1,2,4]triazole-3-carboxylic acid methyl ester [ No CAS ]
  • 23
  • [ 1074-79-9 ]
  • 5-(1-Acetyl-pyrrolidin-2-yl)-1-(2-ethoxycarbonyl-phenyl)-1H-[1,2,4]triazole-3-carboxylic acid methyl ester [ No CAS ]
  • 24
  • [ 1074-79-9 ]
  • [(1-Acetyl-pyrrolidine-2-carbonyl)-amino]-[(2-chloro-pyridin-3-yl)-hydrazono]-acetic acid methyl ester [ No CAS ]
  • 25
  • [ 1074-79-9 ]
  • 2-{N'-[1-[(1-Acetyl-pyrrolidine-2-carbonyl)-amino]-1-methoxycarbonyl-meth-(Z)-ylidene]-hydrazino}-benzoic acid ethyl ester [ No CAS ]
  • 26
  • [ 1074-79-9 ]
  • 2-[(1-Acetyl-pyrrolidine-2-carbonyl)-amino]-2-(2-ethoxycarbonyl-phenylazo)-malonic acid dimethyl ester [ No CAS ]
  • 27
  • [ 1074-79-9 ]
  • 1-(2-Ethoxycarbonyl-phenyl)-5-pyrrolidin-2-yl-1H-[1,2,4]triazole-3-carboxylic acid methyl ester; hydrochloride [ No CAS ]
  • 28
  • [ 23105-58-0 ]
  • [ 1074-79-9 ]
  • 29
  • [ 692-33-1 ]
  • [ 1074-79-9 ]
  • 30
  • [ 56-35-9 ]
  • [ 1074-79-9 ]
  • [ 145344-39-4 ]
  • 31
  • [ 100-39-0 ]
  • [ 1074-79-9 ]
  • benzyl 1-acetylpyrrolidine-2-carboxylate [ No CAS ]
  • 32
  • [ 1262840-25-4 ]
  • [ 1074-79-9 ]
  • C31H41N3O3 [ No CAS ]
  • 33
  • 4-(2-methyl-[1,3']bipyrrolidinyl-1'-yl)-phenylamine [ No CAS ]
  • [ 1074-79-9 ]
  • [ 1146700-33-5 ]
  • 34
  • [ 1146415-36-2 ]
  • [ 1074-79-9 ]
  • [ 1146700-88-0 ]
  • 35
  • [ 1146415-79-3 ]
  • [ 1074-79-9 ]
  • [ 1146700-62-0 ]
 

Historical Records

Technical Information

Categories